Welcome to our dedicated page for Clover Health Investments SEC filings (Ticker: CLOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clover Health Investments, Corp. (Nasdaq: CLOV) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as a publicly traded Medicare Advantage and healthcare technology issuer. Clover Health files reports with the U.S. Securities and Exchange Commission that describe its Medicare Advantage insurance operations, technology platform, financial performance, risk factors, and governance.
Investors can review current reports on Form 8-K, where Clover Health announces material events such as quarterly financial results, CMS Star Ratings for its Medicare Advantage PPO and HMO plans, and board or governance changes. Some 8-K filings also reference supplemental written responses to shareholder questions, offering additional context on strategy, cohort economics, and the role of Clover Assistant and Counterpart Health in the business.
In addition to 8-Ks, Clover Health’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the feed) typically provide detailed discussions of its Insurance segment, Medicare Advantage membership trends, non-GAAP measures such as Adjusted EBITDA and Insurance Benefits Expense Ratio, and regulatory considerations related to Medicare, CMS Star Ratings, and value-based care arrangements.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand how items such as Star Rating changes, CMS rate updates, or shifts in membership mix may affect Clover Health’s reported results. Users can also track insider transaction reports on Form 4 when they appear, to monitor equity transactions by directors and officers.
Filings are updated in near real time from the SEC’s EDGAR system, allowing investors, analysts, and other stakeholders to follow Clover Health’s evolving disclosures on Medicare Advantage performance, technology initiatives through Clover Assistant and Counterpart Health, and corporate governance developments.
Clover Health Investments (CLOV) disclosed a Form 4 for officer Karen M. Soares (General Counsel & Secretary) showing tax-withholding transactions tied to RSU vesting. On 10/31/2025, two Code F entries were reported: 131,521 shares of Class A common stock and 38,086 shares were automatically withheld at a price of $3.53 per share to cover taxes.
The withholding related to performance-based RSUs granted on 10/31/2023, with one-half of earned units settled on 09/13/2024 and the remaining half vesting on 10/31/2025. An additional tranche representing the final 12.5% of RSUs from the same grant also vested on 10/31/2025. Following these transactions, Soares directly beneficially owned 1,236,228 Class A shares.
Clover Health (CLOV) reported insider activity by its officer (CEO, Medicare Advantage), Jamie L. Reynoso. On 10/31/2025, two transactions with code F reflected shares of Class A common stock automatically withheld to cover taxes upon RSU vesting: 101,917 shares related to performance-based RSUs and 29,513 shares related to time-based RSUs, each at $3.53.
Following these withholdings, the reporting person directly beneficially owned 2,823,796 shares. These entries reflect tax withholding tied to previously awarded RSUs and do not represent open-market sales.
Clover Health Investments (CLOV) insider filing: Officer Conrad Wai reported tax-withholding transactions tied to RSU vesting. On 10/31/2025, 96,448 shares of Class A common stock were withheld at $3.53 per share to satisfy taxes for the final 50% of earned performance-based RSUs from an award dated 10/31/2023. On the same date, 27,930 shares were withheld at $3.53 due to vesting of the final 12.5% of time-based RSUs.
Following these transactions, the reporting person beneficially owned 1,150,085 Class A shares directly. In addition, 1,610,482 shares were held indirectly by a family trust for which the reporting person serves as co-trustee. The filing identifies the reporting person as an officer (CEO, Counterpart Health).
Clover Health Investments, Corp. furnished an 8-K stating it issued a press release announcing financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The information in Item 2.02, including Exhibit 99.1, is furnished and not deemed filed under Section 18 of the Exchange Act, and is not incorporated by reference into other filings except as specifically referenced.
Clover Health (CLOV) reported an insider equity transaction by its Chief Financial Officer. On October 29, 2025, 217,382 shares of Class A common stock were automatically withheld at $3.64 per share to cover taxes upon the vesting of a portion of previously granted RSUs.
The vesting represented 6.25% of the original time‑based RSU grant made on April 29, 2024. Following the transaction, the reporting person directly beneficially owns 5,915,209 shares. The remaining RSUs are scheduled to vest in equal quarterly installments through April 29, 2028, subject to continued service.
Clover Health Investments (CLOV) announced that Chelsea Clinton resigned from its Board of Directors and its Talent and Compensation and Nominating and Corporate Governance Committees, effective October 31, 2025. The company states her decision was not due to any disagreement regarding operations, policies, or practices.
The Board’s authorized size remains nine directors, and it will continue to operate with two vacant seats following her departure. The Board intends to fill the vacancy as soon as practicable.
Clover Health (CLOV) reported an insider transaction by its CEO, Medicare Advantage, Jamie L. Reynoso. On 10/17/2025, Reynoso sold 16,514 Class A shares in open market transactions at a $2.69 weighted average price, with trade prices ranging from $2.65 to $2.72. The sale was executed under a Rule 10b5-1 trading plan adopted on March 13, 2025.
Following the sale, Reynoso beneficially owns 2,955,226 shares, held directly.
Clover Health (CLOV) executive Brady Priest (CEO of Home Care) reported a tax‑withholding transaction on October 18, 2025. The filing shows 48,305 shares of Class A common stock were automatically withheld at $2.71 per share upon RSU vesting (Transaction Code F), leaving 2,340,274 shares beneficially owned directly.
The shares relate to vesting of 6.25% of time‑based RSUs granted on July 18, 2022. The remaining RSUs have a final vesting date on July 18, 2026, contingent on continued service.
Clover Health Investments, Corp. (CLOV) reported an insider transaction on a Form 4. An officer (CEO of Home Care) had 82,778 shares of Class A Common Stock automatically withheld at $2.8 on 10/15/2025 to cover taxes from restricted stock unit (RSU) vesting (Transaction Code F).
Following the withholding, the reporting person directly beneficially owns 2,388,579 shares. The RSUs were granted on 10/15/2024; 25% vested on 10/15/2025, with the remainder vesting quarterly in 6.25% increments through 10/15/2028, subject to continued service.
Clover Health (CLOV) reported an insider transaction by CEO and Director Andrew Toy. On 10/15/2025, 242,580 shares of Class A Common Stock were withheld at $2.8 per share (transaction code F) to cover tax obligations arising from RSU vesting. Following this administrative withholding, Toy beneficially owns 9,922,982 shares directly.
The withheld shares relate to RSUs granted on 10/15/2024, with 25% vesting on 10/15/2025. The remaining RSUs vest quarterly in equal 6.25% installments through 10/15/2028, subject to continued service.